3M CO Q4 FY2024 earnings call

2024 was a pivotal year for 3M with the spin-off of the Healthcare Business Group as Solventum, settlement of significant legal matters, and the completion of the largest restructuring program in company history. In the fourth quarter, adjusted earnings per share was $1.68 on a 2.1% organic revenue growth. All business groups drove positive adjusted organic growth in the fourth quarter. 2024 saw the launch of 169 new products, which was a 32% increase from the prior year. There was a focus on improving service levels with on-time, in-full (OTIF) at 88% for the year, an increase of 3 percentage points compared to the previous year. The goal is to reduce inventory days to 75 days. In 2024, $3.8 billion was returned to shareholders.

In the fourth quarter, Safety & Industrial organic sales grew for the third consecutive quarter with a 2.4% growth, and this growth was broad-based with six out of seven divisions posting positive growth. For the year, Safety & Industrial had an organic sales growth of 0.7%. Transportation & Electronic adjusted sales saw a 2% organic growth in the fourth quarter, and for the year, it had an organic growth of 3.4%. The Consumer business returned to growth in the fourth quarter with a 1.2% organic growth, but for the year, it was down 1.2%.

For 2025, 3M expects organic sales growth in the range of 2% to 3%, adjusted earnings per share in the range of $7.60 to $7.90, and a free cash flow conversion of approximately 100%. It is expected that all business groups will achieve low-single-digit growth, supported by commercial excellence, improvement in service levels, and new product launches.

Risks include potential impacts from exchange rate fluctuations, challenges in improving service levels in certain business segments, and uncertainties in the macroeconomic environment that could affect growth.

Q: Just on the top-line in particular, to what degree sort of the operational execution -- product development has actually impacted the top-line already versus what you expect to kind of play out in 2025.

A: New product introductions came in above expectations, but many of them are incremental. More impact from higher octane products is expected in 2025. 50 people were added in the fourth quarter and about 100 people were moved into R&D development.

Q: A lot of conversation last year on restructuring versus stranded costs. Within that $0.70 to $1 bridge item, granularity on restructuring investments and stranded costs.

A: Sales volume, lower restructuring cost, and net productivity contribute to the bridge. Volume growth, lower restructuring cost, and net productivity provide tailwinds, which offset growth investments and stranded costs.

Q: What you're trying to change with the sales organization and quota pull-forward.

A: Quota pull-forward is to make sales leaders and reps know their targets early. The focus is on selling existing products better, there is a cross-selling pilot, and changes in pricing. Improvement in on-time, in-full performance is needed.

Q: Skeptical about 1.9% IPI forecast. Haircuts taken and pricing in 2025.

A: Entered 2025 with a higher IPI expectation than the current one, but 2%-3% organic growth is felt to be appropriate. Pricing is included in the organic growth expectations.

Q: Margin guidance by segment and T&E margin in Q4.

A: Q4 margins were better than expected. TEBG margins were lower in Q4 due to seasonality, growth investments, and foreign exchange. Margin expansion across all segments is expected in 2025.

Q: Free cash flow conversion and working capital in 2025.

A: A 100% free cash flow conversion is expected. The goal is to improve working capital to 75 days, offsetting the impact of receivables with inventory control.

Q: Industrial OTIF and manufacturing DC footprint.

A: Progress in SIBG OTIF is expected in early 2025. Focus is on improving operations, addressing quality and asset issues. There is a long-term plan for operational excellence including factory improvement and network efficiency.

Q: China outlook and insurance recovery.

A: China revenue is expected to be in the low single-digit range in 2025. There has been progress on insurance recovery with $340 million recovered so far, and active participation in arbitration and litigation.

Q: Cash and industrial production focus.

A: Cash is expected to end 2025 at over $6 billion. Focus is on U.S. and Europe industrial production, auto builds, and gaining share in growing automakers.

Q: Innovation and inventory reduction trade-off.

A: Support for 15% unbudgeted time for innovation. On-time, in-full performance is prioritized over inventory reduction, aiming for both 75 days inventory and over 90% OTIF.